Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Buchacher, L; Richtig, G; Dernoscheg, M; Richtig, E; Koch, L.
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
J Eur Acad Dermatol Venereol. 2023; 37(5):e605-e607
Doi: 10.1111/jdv.18871
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Koch Lukas
- Co-authors Med Uni Graz
- Dernoscheg Marie-Therese
- Richtig Erika
- Richtig Georg
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Proto-Oncogene Proteins B-raf - administration & dosage
- Drug Tapering - administration & dosage
- Melanoma - pathology
- Skin Neoplasms - pathology
- Mitogen-Activated Protein Kinase Kinases - therapeutic use
- Protein Kinase Inhibitors - adverse effects
- Antineoplastic Combined Chemotherapy Protocols - adverse effects